Ozempic (Semaglutide) 1.34mg/mL China | GLP-1 RA | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Information: Ozempic (China-Mainland)

Ozempic (诺和泰, semaglutide) is the China-Mainland brand of semaglutide injection, a once-weekly GLP-1 receptor agonist developed by Novo Nordisk for the treatment of type 2 diabetes. It is supplied as a clear, colourless solution in pre-filled injection pens at a concentration of 1.34 mg/mL, in two presentations — a 1.5 mL pen and a 3 mL pen. In China, Ozempic is approved for glycaemic control, cardiovascular protection and kidney protection in adults with type 2 diabetes, and it is reimbursed through the national medical insurance drug list.

What Is Semaglutide Used For?

Semaglutide (Ozempic) is used to improve blood-glucose control in adults with type 2 diabetes, as an adjunct to diet and exercise. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of kidney function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Semaglutide is a member of the GLP-1 receptor agonist class and shares a high degree of structural similarity with the natural human GLP-1 hormone.

How Does Semaglutide Work?

Semaglutide mimics the action of glucagon-like peptide-1 (GLP-1), a gut hormone released after eating. It binds to and activates the GLP-1 receptor to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying and reduce appetite. Because insulin release is triggered only when blood glucose is elevated, semaglutide lowers glucose without a high risk of hypoglycaemia on its own. Its long half-life — about one week — makes once-weekly dosing possible.

Indications

In China-Mainland, Ozempic (semaglutide) is indicated for: (1) glycaemic control in adults with type 2 diabetes whose blood glucose is inadequately controlled despite metformin and/or sulfonylurea therapy, on the basis of diet and exercise; (2) reduction of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, in adults with type 2 diabetes and established cardiovascular disease; and (3) reduction of the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

Dosage

Ozempic is given by subcutaneous injection once weekly, at any time of day, with or without meals. Treatment starts at 0.25 mg once weekly for the first four weeks to improve tolerability, after which the dose is increased to 0.5 mg once weekly. If additional glycaemic control is needed, the dose may be increased to 1 mg once weekly after at least four weeks on the 0.5 mg dose. The 1.5 mL pen contains about 2 mg of semaglutide and the 3 mL pen about 4 mg. The injection site may be the abdomen, thigh or upper arm, and the exact dose and schedule should follow the prescribing physician's instructions.

Side Effects

The most common adverse reactions to semaglutide are gastrointestinal, including nausea, vomiting, diarrhoea, abdominal pain and constipation, which are usually mild to moderate and tend to diminish over time. Hypoglycaemia may occur, particularly when semaglutide is combined with insulin or sulfonylureas. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in those with multiple endocrine neoplasia syndrome type 2. Patients should be monitored for signs of pancreatitis and diabetic retinopathy complications, and the prescribing physician should be informed of any concerning symptoms.

Storage

Before first use, Ozempic pens should be stored in a refrigerator at 2°C to 8°C, away from the freezing element, and must not be frozen. After first use, the pen may be kept either at room temperature up to 30°C or in a refrigerator at 2°C to 8°C for up to six weeks. The pen cap should be kept on to protect the medicine from light, and the needle should be removed and discarded after each injection. The pen is for single-patient use only.

Why Choose the China Version of Ozempic?

The China-Mainland Ozempic is the locally registered, NMPA-approved presentation of semaglutide, backed by Novo Nordisk's global development programme and reimbursed through China's national medical insurance drug list. For patients and institutions seeking a reliable once-weekly GLP-1 receptor agonist for type 2 diabetes and its cardiovascular and renal complications, sourcing through GLT adds verification of authenticity, cold-chain integrity and the complete export documentation needed for cross-border procurement, keeping the process transparent and traceable.

How to Order

To source China-Mainland Ozempic (semaglutide) through GLT, contact us on WhatsApp at +86 15234153837 or email [email protected]. Tell us the pen presentation you need (1.5 mL or 3 mL), the quantity and your destination, and we will confirm current stock, cold-chain logistics and the import documentation required. A valid prescription is required, and we serve both institutions and individual patients.

FAQ

What is the Chinese brand name of Ozempic? In China, Ozempic (semaglutide) is known as 诺和泰 and is marketed by Novo Nordisk.

Is Ozempic the same as Wegovy? Both contain semaglutide, but they are different products. Ozempic is approved for type 2 diabetes, whereas Wegovy is a higher-dose semaglutide formulation approved for weight management in certain markets. This product page is for Ozempic (诺和泰), the diabetes indication.

Is semaglutide available as an oral tablet? Yes, an oral semaglutide tablet (Rybelsus) exists, but Ozempic is the injectable formulation given once weekly by subcutaneous injection. They are different dosage forms.

Is semaglutide covered by medical insurance in China? Yes. Ozempic (semaglutide) is reimbursed through China's national medical insurance drug list, which lowers the out-of-pocket cost for eligible patients.

How often is Ozempic injected? Ozempic is injected once weekly, starting at 0.25 mg for four weeks and then increasing to 0.5 mg or 1 mg as prescribed.

Related Oncology Products

Zepbound (Tirzepatide) 2.5–15mg/0.5mL Single-Dose Pen | Eli Lilly USA | GLT

Zepbound — Eli Lilly tirzepatide single-dose pen, six US strengths (2.5–15mg/0.5mL) for chronic weight management...

Orforglipron (LuciOrfor) 0.8–17.2mg Tablets | Laos Generic Oral GLP-1 | GLT

Lucius Pharmaceuticals (Laos) generic orforglipron, 6-dose titration for weight management

Mounjaro KwikPen (Tirzepatide) 10–60mg/2.4mL Multi-Dose | Eli Lilly USA | GLT

Mounjaro KwikPen — Eli Lilly single-patient multi-dose pen, six US strengths (10–60mg/2.4mL, 4 doses each)...

Tirzema (Tirzepatide) 2.5/5/7.5mg/0.5mL Single-Dose Pen | Incepta Bangladesh | GLT

Tirzema — Incepta Pharmaceuticals tirzepatide single-dose pen, three official strengths (2.5/5/7.5mg/0.5mL) for T2DM and weight...

Tixepa (Tirzepatide) 20mg/2mL & 30mg/2mL Multi-Dose Pen | Drug International | GLT

Tixepa — Drug International Limited (DIL) tirzepatide multi-dose pen, two official strengths (Tixepa-5 = 20mg/2mL,...